Coscelli C, Iacobellis G, Calderini C, Carleo R, Gobbo M, Di Mario U, Leonetti F, Galluzzo A, Pirrone V, Lunetta M, Casale P, Paleari F, Falcelli C, Valle D, Camporeale A, Merante D
Department of Internal Medicine and Metabolic Diseases, Parma Hospital, Parma, Italy.
Acta Diabetol. 2003 Dec;40(4):187-92. doi: 10.1007/s00592-003-0110-2.
We investigated the use, in a short period, of Humalog Mix25 (Mix25) in a twice-daily administration regimen compared to a twice-daily injection therapy with Humulin 30/70 (30/70) in diabetic patients with Italian dietary habits. We studied 33 type 2 diabetic patients aged 59.1 +/- 8.1 years, BMI 29.8 +/- 2.7 kg/m2, duration of diabetes and insulin therapy of 14.4 +/- 9.8 and 4.2 +/- 4.6 years, respectively. After a 4-day lead-in period of twice-daily human insulin 30/70 treatment, patients were randomized to one of two treatment sequences: (1) a twice-daily regimen with Mix25 just 5 minutes before the morning and evening meals for 12 days, followed by a twice-daily therapy with human insulin 30/70 given 30 minutes before the morning and evening meals for an additional 12 days; or (2) the alternate sequence. Each patient underwent a mixed meal test: Humulin 30/70 was administered 30 minutes before the meal, while Mix25 was given 5 minutes before. The 2-hour post-prandial glucose concentration after breakfast was significantly lower during treatment with Mix25 than with Humulin 30/70 (157 +/- 43.2 vs. 180 +/- 43.2 mg/dl, p<0.05). The glycemic excursion after dinner on Mix25 treatment was significantly lower than with Humulin 30/70 (12.2 +/- 48.01 vs. 35.5 +/- 36.92 mg/dl, p<0.05). AUCglucose after Mix25 was lower than after Humulin 30/70. Glycemia after test meal was significantly lower with Mix25 than with Humulin 30/70. Insulin and free insulin concentrations after the test meal were significantly higher with Mix25 in comparison to Humulin 30/70. AUC serum insulin and free insulin curves after Mix25 were significantly higher than after Humulin 30/70 (p=0.028 and p=0.005, respectively). Twice-daily injections of Humalog Mix25, compared to human insulin 30/70 in type 2 diabetic patients with Italian dietary habits, provide improved and lasting post-prandial glycemic control, with the great convenience of the injection just before the meal.
我们研究了在意大利饮食习惯的糖尿病患者中,短期内将优泌乐25(Mix25)用于每日两次给药方案,并与每日两次注射优泌林70/30(30/70)进行比较。我们研究了33例2型糖尿病患者,年龄59.1±8.1岁,体重指数29.8±2.7kg/m²,糖尿病病程和胰岛素治疗时间分别为14.4±9.8年和4.2±4.6年。在每日两次注射人胰岛素30/70的4天导入期后,患者被随机分为两个治疗顺序之一:(1)每日两次方案,在早晚餐前5分钟注射Mix25,共12天,然后在早晚餐前30分钟每日两次注射人胰岛素30/70,再持续12天;或(2)交替顺序。每位患者都接受了混合餐试验:优泌林30/70在餐前30分钟注射,而Mix25在餐前5分钟注射。早餐后用Mix25治疗期间2小时餐后血糖浓度显著低于用优泌林30/70治疗时(157±43.2对180±43.2mg/dl,p<0.05)。Mix25治疗晚餐后的血糖波动显著低于优泌林30/70(12.2±48.01对35.5±36.92mg/dl,p<0.05)。Mix25后的葡萄糖曲线下面积低于优泌林30/70。试验餐后Mix25的血糖显著低于优泌林30/70。试验餐后Mix25的胰岛素和游离胰岛素浓度显著高于优泌林30/70。Mix25后的血清胰岛素和游离胰岛素曲线下面积显著高于优泌林30/70(分别为p=0.028和p=0.005)。在有意大利饮食习惯的2型糖尿病患者中,与优泌林30/70相比,每日两次注射优泌乐Mix25可改善并持久控制餐后血糖,且在餐前注射极为方便。